PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-12 pm EDT
50.11 USD   +3.77%
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts

06/27/2022 | 10:43am EDT

NEW YORK - Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2022 Performance Report, to be issued that morning.

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.

You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada. The password is 'PFEQ222'.

The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice

The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; and our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) and our oral COVID-19 treatment (Paxlovid), that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned 'Risk Factors' and 'Forward-Looking Information and Factors That May Affect Future Results', as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Contact:

Media

E: PfizerMediaRelations@Pfizer.com

T: +1 (212) 733-1226

Investors

E: IR@Pfizer.com

T: +1 (212) 733-4848

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
08/12Creighton students' COVID vaccine mandate appeal dismissed
AQ
08/12Drugmakers' shares up after Zantac lawsuit slump
RE
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/12Oncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational..
AQ
08/12There are two ways to see inflation data
MS
08/12Pfizer Says Pneumococcal Disease Vaccine Has Potential to Provide Broadest Serotype Cov..
MT
08/12Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal..
BU
08/12Pfizer Inc. Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumoc..
CI
08/12GSK, Sanofi, Haleon Shares Recover Some Recent Losses After Zantac Drug Responses
DJ
08/12Haleon Says It Hasn't Been Notified About Litigation on Zantac Drug -- Update
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,89x
Yield 2022 3,23%
Capitalization 281 B 281 B -
EV / Sales 2022 2,65x
EV / Sales 2023 3,37x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 50,11 $
Average target price 56,53 $
Spread / Average Target 12,8%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.14%281 235
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550